These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34697718)

  • 1. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
    Chambers JD; Margaretos NM; Enright DE; Wang R; Ye X
    Pharmacoeconomics; 2022 Feb; 40(2):225-232. PubMed ID: 34697718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 3. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 4. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
    Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
    [No Abstract]   [Full Text] [Related]  

  • 5. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs.
    Chambers JD; Silver MC; Berklein FC; Cohen JT; Neumann PJ
    J Gen Intern Med; 2020 Sep; 35(9):2629-2636. PubMed ID: 32291711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
    Yu T; Jin S; Li C; Chambers JD; Hlávka JP
    BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in US private health plans' coverage of orphan drugs.
    Chambers JD; Panzer AD; Kim DD; Margaretos NM; Neumann PJ
    Am J Manag Care; 2019 Oct; 25(10):508-512. PubMed ID: 31622066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specialty Drug Coverage Varies Across Commercial Health Plans In The US.
    Chambers JD; Kim DD; Pope EF; Graff JS; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2018 Jul; 37(7):1041-1047. PubMed ID: 29985695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
    Picavet E; Cassiman D; Simoens S
    J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs.
    Clifford KA; Levine AA; Enright DE; Neumann PJ; Chambers JD
    Value Health; 2024 Jul; ():. PubMed ID: 39094687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' access to 2018 FDA-approved drugs 1 year post approval.
    Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
    Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures.
    Chambers J; Pope E; Bungay K; Cohen J; Ciarametaro M; Dubois R; Neumann PJ
    Value Health; 2018 Apr; 21(4):400-406. PubMed ID: 29680096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of prescriber requirements among US commercial health plans.
    Lenahan K; Panzer AD; Gertler R; Chambers JD
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
    Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
    J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
    Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value-Based?
    Cohen JP; Khoury CE; Milne CP; Peters SM
    Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):2758-2769. PubMed ID: 29047143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.